Pain management programme leads to radical reduction in opioid prescriptions

A new pain management programme implemented by surgeons in large healthcare systems led to a 64% reduction in opioid prescriptions of five or more days.

Although the role of prescriptions is widely documented in the ongoing US opioid epidemic, it’s only recently been shown that prescriptions lasting longer than five days have been identified as a risk factor for longer-term opioid use.

As some surgeons’ prescribing patterns have been found to be part of the problem, the surgical community is now working hard to address it.

A recent solution has been enacted by a large healthcare system in central Texas, where surgeons implemented a pain management programme that reduced longer-term prescriptions by two-thirds, according to a study published in the Journal of the American College of Surgeons.

The programme reduced post-surgery opioid prescriptions at Baylor Scott & White (BSW) hospitals of more than five days by 64%, from 1,228 in the three months before the programme started to 432 in the first three months of 2019. Prescriptions of less than five days duration increased 15%, from 5,133 to 5,923.

“Opioid prescriptions of over five days have been shown to dramatically increase addiction to opioids,” said lead study author Richard Frazee, a general surgeon at BSW Healthcare in Temple, Texas. “We established a standard of opioid prescriptions of five days or less after elective surgery.”

The programme consisted of using the monthly surgical grand rounds – a conference of a hospital’s physicians, residents and medical students – to educate surgeons and anaesthesiologists about the opioid epidemic and how post-surgery opioid prescriptions contributed to it.

At these meetings, the rationale for limiting opioid prescriptions to five days or less was introduced. The program also used the electronic health record (EHR) to monitor each physician’s opioid prescribing practices and, after six months, tied this measure to the quality component of their compensation.

Overall, the study included 31,814 patients who had elective surgery at the hospitals from January 2018, when the program began, through March 2019. Over the five quarters the study observed, a greater proportion of opioid prescriptions shifted from more than five days to fewer than five days.

Changing the way surgeons prescribe pain medication after surgery was not easy, Dr. Frazee acknowledged. The researchers noted that surgeons’ prescribing patterns have been slow to respond nationally to the opioid crisis, citing a Kaiser Health News-Johns Hopkins analysis that found that surgeons frequently wrote prescriptions of 100 pills or more from 2011 to 2016.

“As always, to change surgeons’ behaviour you have to convince them that it is a benefit to their patients,” he said. “We had to overcome many years of misinformation on the ‘safety’ of liberal use of opioids after surgery.”

The programme is one that can easily be used in other hospitals and health systems, Dr. Frazee said.

“This is an issue that health-care providers and the public are increasingly aware of. The Baylor Scott & White Healthcare System has adopted and emphasised a culture of safety. This program offers a model for other health-care systems and individual surgeons to adopt in the care of their patients.”

But tackling opioid addiction requires a multipronged approach. “The opioid crisis is ongoing; this study is one step in the process to addressing it,” Dr. Frazee said. “A continued multipronged approach is needed that incorporates education, pharmaceutical reform, rehabilitation programs, and easy disposal of unneeded prescriptions.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Related news

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...